

NOVEN PHARMACEUTICALS INC  
Form 8-K  
November 19, 2004

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 16, 2004

Noven Pharmaceuticals, Inc

(Exact name of registrant as specified in its charter)

Delaware

0-17254

59-2767632

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

11960 S.W. 144th Street, Miami, Florida

33186

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

305-253-5009

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Top of the Form**

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On November 16, 2004, the Board of Directors ("Board") of Noven Pharmaceuticals, Inc. (the "Company") increased the size of the Board to seven persons and appointed Pedro P. Granadillo as a new member of the Board. Mr. Granadillo was also appointed to the Company's Compensation and Stock Option Committee. A copy of the press release issued by the Company announcing Mr. Granadillo's appointment to the Board is attached as an exhibit to this report.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release of Noven Pharmaceuticals, Inc. dated November 19, 2004.

[Remainder of page left blank intentionally]

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Noven Pharmaceuticals, Inc

*November 19, 2004*

By: */s/ Jeffrey F. Eisenberg*

---

*Name: Jeffrey F. Eisenberg*

*Title: Vice President - Strategic Alliances, General Counsel  
and Corporate Secretary*

---

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Noven Pharmaceuticals, Inc. dated November 19, 2004.